Статья

New targets for HIV drug discovery

A. Puhl, D. Garzino, V. Makarov, S. Ekins,
2021

Recent estimates suggest close to one million people per year die globally owing to HIV-related illnesses. Therefore, there is still a need to identify new targets to develop future treatments. Many of the more recently identified targets are host-related and these might be more difficult for the virus to develop drug resistance to. In addition, there are virus-related targets (capsid and RNAse H) that have yet to be exploited clinically. Several of the newer targets also address virulence factors, virus latency or target persistence. The targets highlighted in this review could represent the next generation of viable candidates for drug discovery projects as well as continue the search for a cure for this disease. © 2019 Elsevier Ltd

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • A. Puhl
    Collaborations Pharmaceuticals, Inc., Main Campus Drive, Lab 3510, Raleigh, NC 27606, United States
  • D. Garzino
    Department of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, MD, United States
  • V. Makarov
    Institute for Human Virology, University of Maryland, School of Medicine, Baltimore, MD, United States
  • S. Ekins
    Department of Molecular Medicine, University of Padova, Padova, Italy
Название журнала
  • Drug Discovery Today
Том
  • 24
Выпуск
  • 5
Страницы
  • 1139-1147
Ключевые слова
  • activated leukocyte cell adhesion molecule; amyloid protein; anti human immunodeficiency virus agent; CD4 antigen; cyclophilin A; cytidine deaminase; ecalectin; histone; histone deacetylase; Ku antigen; lens epithelium derived growth factor; macrophage inflammatory protein; mammalian target of rapamycin; mucosa associated lymphoid tissue lymphoma translocation protein 1; Nef protein; nucleophosmin; phosphoprotein phosphatase 1; protein disulfide isomerase; protein tyrosine kinase; ribonuclease H; solute carrier family 35 member b2; toll like receptor 4; transactivator protein; tyrosylprotein sulfotransferase 2; unclassified drug; virulence factor; Y box binding protein 1; anti human immunodeficiency virus agent; CD4+ T lymphocyte; cell viability; clustered regularly interspaced short palindromic repeat; dendritic cell; drug targeting; genome-wide association study; human; Human immunodeficiency virus; nonhuman; oncogene src; protein cleavage; Review; screening test; virus capsid; virus latency; animal; drug development; Human immunodeficiency virus infection; metabolism; molecularly targeted therapy; Animals; Anti-HIV Agents; Drug Discovery; HIV Infections; Humans; Molecular Targeted Therapy
Издатель
  • Elsevier Ltd
Тип документа
  • Review
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus